Oppenheimer Asset Management’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.08M | Sell |
25,283
-76,431
| -75% | -$4.15M | 0.01% | 732 |
|
|
2026
Q1 | $6.38M | Sell |
101,714
-85,172
| -46% | -$6.81M | 0.07% | 287 |
|
|
2025
Q4 | $17.8M | Sell |
186,886
-21,543
| -10% | -$2.11M | 0.22% | 113 |
|
|
2025
Q3 | $20.3M | Buy |
208,429
+95,402
| +84% | +$9.88M | 0.22% | 105 |
|
|
2025
Q2 | $12.1M | Buy |
113,027
+2,427
| +2% | +$246K | 0.14% | 173 |
|
|
2025
Q1 | $11.2M | Sell |
110,600
-3,862
| -3% | -$389K | 0.14% | 174 |
|
|
2024
Q4 | $10.2M | Buy |
114,462
+196
| +0.2% | +$17.3K | 0.12% | 183 |
|
|
2024
Q3 | $9.58M | Sell |
114,266
-1,385
| -1% | -$109K | 0.12% | 200 |
|
|
2024
Q2 | $8.91M | Buy |
115,651
+15,216
| +15% | +$1.11M | 0.11% | 212 |
|
|
2024
Q1 | $6.88M | Sell |
100,435
-8,176
| -8% | -$526K | 0.1% | 229 |
|
|
2023
Q4 | $6.28M | Sell |
108,611
-1,745
| -2% | -$93.1K | 0.09% | 262 |
|
|
2023
Q3 | $5.83M | Buy |
110,356
+77,051
| +231% | +$4.04M | 0.09% | 253 |
|
|
2023
Q2 | $1.8M | Sell |
33,305
-13,109
| -28% | -$685K | 0.03% | 537 |
|
|
2023
Q1 | $2.32M | Sell |
46,414
-968
| -2% | -$45.6K | 0.04% | 453 |
|
|
2022
Q4 | $2.19M | Buy |
47,382
+7,079
| +18% | +$307K | 0.04% | 448 |
|
|
2022
Q3 | $1.56M | Sell |
40,303
-71
| -0.2% | -$2.85K | 0.03% | 525 |
|
|
2022
Q2 | $1.5M | Sell |
40,374
-864
| -2% | -$35.2K | 0.03% | 552 |
|
|
2022
Q1 | $1.83M | Sell |
41,238
-696
| -2% | -$30.2K | 0.03% | 564 |
|
|
2021
Q4 | $1.78M | Sell |
41,934
-3,395
| -7% | -$143K | 0.02% | 587 |
|
|
2021
Q3 | $1.97M | Buy |
45,329
+28,627
| +171% | +$1.27M | 0.03% | 541 |
|
|
2021
Q2 | $715K | Buy |
16,702
+54
| +0.3% | +$2.27K | 0.01% | 849 |
|
|
2021
Q1 | $643K | Sell |
16,648
-920
| -5% | -$34.8K | 0.01% | 853 |
|
|
2020
Q4 | $631K | Sell |
17,568
-38,161
| -68% | -$1.38M | 0.01% | 821 |
|
|
2020
Q3 | $2.13M | Buy |
55,729
+2,085
| +4% | +$80.3K | 0.04% | 420 |
|
|
2020
Q2 | $1.88M | Sell |
53,644
-14,811
| -22% | -$533K | 0.04% | 417 |
|
|
2020
Q1 | $2.23M | Buy |
68,455
+14,669
| +27% | +$573K | 0.05% | 330 |
|
|
2019
Q4 | $2.43M | Buy |
53,786
+920
| +2% | +$38.5K | 0.05% | 372 |
|
|
2019
Q3 | $2.15M | Buy |
52,866
+7,170
| +16% | +$304K | 0.05% | 387 |
|
|
2019
Q2 | $1.96M | Buy |
45,696
+129
| +0.3% | +$4.96K | 0.04% | 413 |
|
|
2019
Q1 | $1.75M | Buy |
45,567
+5,655
| +14% | +$216K | 0.04% | 436 |
|
|
2018
Q4 | $1.41M | Sell |
39,912
-67
| -0.2% | -$2.43K | 0.03% | 460 |
|
|
2018
Q3 | $1.54M | Buy |
39,979
+1,555
| +4% | +$54.3K | 0.03% | 493 |
|
|
2018
Q2 | $1.26M | Buy |
38,424
+190
| +0.5% | +$5.73K | 0.03% | 536 |
|
|
2018
Q1 | $1.04M | Buy |
38,234
+2,143
| +6% | +$58.2K | 0.03% | 587 |
|
|
2017
Q4 | $1.05M | Hold |
36,091
| – | – | 0.03% | 581 |
|
|
2017
Q3 | $1.05M | Buy |
36,091
+106
| +0.3% | +$2.93K | 0.03% | 584 |
|
|
2017
Q2 | $997K | Sell |
35,985
-345
| -0.9% | -$9.16K | 0.03% | 580 |
|
|
2017
Q1 | $903K | Buy |
+36,330
| New | +$883K | 0.03% | 604 |
|
Other funds holding BSX
Oppenheimer Asset Management's BSX Position: Q2 2026 in Review
Oppenheimer Asset Management reduced its Boston Scientific (BSX) stake by 75% in Q2 2026, selling an estimated $4.15M and leaving 25,283 shares worth $1.08M. The position accounts for 0.01% of the portfolio, ranked #732.
Oppenheimer Asset Management first reported a position in BSX in Q1 2017 and has held it in 38 quarters since. The position peaked at $20.3M in Q3 2025. 1,487 funds tracked by Wall St. Rank hold BSX as of Q2 2026.
- Oppenheimer Asset Management held 25,283 shares of Boston Scientific worth $1.08M as of Q2 2026.
- Oppenheimer Asset Management sold 76,431 Boston Scientific shares in Q2 2026, an estimated $4.15M.
- Boston Scientific made up 0.01% of Oppenheimer Asset Management's portfolio in Q2 2026, its #732 holding.
- Oppenheimer Asset Management first reported a position in Boston Scientific in Q1 2017 and has held it in 38 quarters since.
- Oppenheimer Asset Management's Boston Scientific position peaked at $20.3M in Q3 2025.
- 1,487 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.
Based on Oppenheimer Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.